Review Article
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review
Table 4
Standard mean difference and event rates.
| Group | Outcome | Standard mean difference/event rates | Number of studies | Mean | 95% CI |
| Conbercept | Polyp regression rate | 0.683 | 0.552 to 0.790 | 3 | BCVA | 0.305 | 0.097 to 0.513 | 4 | CRT | 1.083 | 0.690 to 1.476 | 4 | Injection frequency | 5.533 | 4.789 to 6.276 | 4 | Adverse events | 0.026 | 0.003 to 0.175 | 5 |
| Ranibizumab | Polyp regression rate | 0.324 | 0.276 to 0.376 | 6 | BCVA | 0.274 | 0.127 to 0.421 | 9 | CRT | 0.819 | 0.688 to 0.950 | 5 | Injection frequency | 5.030 | 4.267 to 5.793 | 4 | Adverse events | 0.040 | 0.023 to 0.068 | 12 |
| Aflibercept | Polyp regression rate | 0.496 | 0.411 to 0.582 | 11 | BCVA | 0.673 | 0.380 to 0.966 | 13 | CRT | 1.435 | 1.098 to 1.772 | 15 | Injection frequency | 6.811 | 6.176 to 7.445 | 5 | Adverse events | 0.042 | 0.022 to 0.077 | 10 |
|
|